EUDA Health Holdings Ltd (EUDA) Form 6-K — Jul 31, 2026
EUDA Health Holdings Limited announced a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd to advance an integrated iPSC cell therapy program for oncology and wellness. Under the agreement, EUDA intends to fund the collaboration and facilitate commercialization, leveraging GO POSB's proprietary iPSC platform and SIIT's cell engineering capabilities to develop off-the-shelf therapies.
Key figures
- Aging Population Percent
- 30%
- Target Market Population
- 1.8 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.